Exposure‐Response Analyses of Upadacitinib Efficacy and Safety in Phase 2 and 3 Studies to Support Benefit‐Risk Assessment in Rheumatoid Arthritis
Clinical Pharmacology and Therapeutics - United States
doi 10.1002/cpt.1671
Full Text
Open PDFAbstract
Available in full text
Categories
Date
November 30, 2019
Authors
Publisher
Wiley